about 1%-2% of patients with chronic refractory pouchitis, in the context of ulcerative colitis, end up with a permanent ileostomy. The aim of this systematic review was to collect all published studies involving patients treated with vedolizumab for chronic refractory or antibiotic-dependent pouchitis and then pool the data regarding the effectiveness of this therapeutic strategy.

Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis

Ribaldone, Davide Giuseppe;Pellicano, Rinaldo;Saracco, Giorgio Maria;Morino, Mario;
2020-01-01

Abstract

about 1%-2% of patients with chronic refractory pouchitis, in the context of ulcerative colitis, end up with a permanent ileostomy. The aim of this systematic review was to collect all published studies involving patients treated with vedolizumab for chronic refractory or antibiotic-dependent pouchitis and then pool the data regarding the effectiveness of this therapeutic strategy.
2020
112
59
63
Ribaldone, Davide Giuseppe; Pellicano, Rinaldo; Saracco, Giorgio Maria; Morino, Mario; Astegiano, Marco
File in questo prodotto:
File Dimensione Formato  
ArticuloDOI_6336.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 541.25 kB
Formato Adobe PDF
541.25 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1720667
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 14
social impact